Discover 1,248 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,248
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
for
Central Line Associated Blood Stream Infections (CLABSI)
Location: Nashville TN, Atlanta GA, Chicago IL, Iowa City IA,
Sponsor: CorMedix Therapeutics
Sex: All
Age: 18+
Code: NCT06822426
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
New
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
for
Metastatic Malignant Neoplasm
Location: Nashville TN, Fairfax VA, Baltimore MD, Houston TX,
Sponsor: NextPoint Therapeutics, Inc.
Sex: All
Age: 19+
Code: NCT07563829
Phase1, Recruiting
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Nashville TN, Cincinnati OH, St Louis MO, Columbus OH,
Sponsor: Fate Therapeutics
Sex: All
Age: 18+
Code: NCT06241456
Phase1, Recruiting
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
for
Advanced or Metastatic Breast Cancer
Location: Nashville TN
Sponsor: Kind Pharmaceuticals LLC
Sex: Female
Age: 18+
Code: NCT05187832
Phase1, Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
for
Small Cell Lung Cancer
Location: Nashville TN, Chicago IL, Milwaukee WI, Buffalo NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06780137
Phase1, Phase2, Recruiting
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
for
Non-small Cell Lung Cancer (NSCLC)
Location: Nashville TN, Houston TX
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT06567015
Phase1, Phase2, Recruiting
SNV1521 in Participants With Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Nashville TN, Toronto, Houston TX, Philadelphia PA,
Sponsor: Synnovation Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06220864
Phase1, Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
for
Prostate Cancer,
Location: Nashville TN, Birmingham AL, Cincinnati OH, St Louis MO,
Sponsor: Janux Therapeutics
Sex: Male
Age: 18 - 70+
Code: NCT05519449
Phase1, Recruiting
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
for
Relapsed Classic Hodgkin Lymphoma
Location: Nashville TN, Chicago IL, Hackensack NJ, Boston MA,
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT04561206
Phase2, Recruiting
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
for
Triple Negative Breast Cancer, Breast Cancer,
Location: Nashville TN, Atlanta GA, Chicago IL, Detroit MI,
Sponsor: Day One Biopharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT05377996
Phase1, Phase2, Recruiting
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
for
Metastatic Uveal Melanoma
Location: Nashville TN, Knoxville TN, Germantown TN, Atlanta GA,
Sponsor: Replimune Inc.
Sex: All
Age: 0+
Code: NCT06581406
Phase2, Phase3, Recruiting
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
for
Cancer
Location: Nashville TN, Cincinnati OH, Grand Rapids MI, Paris TX,
Sponsor: Tizona Therapeutics, Inc
Sex: All
Age: 18+
Code: NCT04485013
Phase1, Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
for
Triple Negative Locally Advanced Non-resectable Breast Cancer,
Location: Nashville TN, Columbus OH, Toronto, San Antonio TX,
Sponsor: Marengo Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06827613
Phase1, Phase2, Recruiting
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors